These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27807998)

  • 1. Discovery and pharmacological effects of a novel GPR142 antagonist.
    Murakoshi M; Kuwabara H; Nagasaki M; Xiong YM; Reagan JD; Maeda H; Nara F
    J Recept Signal Transduct Res; 2017 Jun; 37(3):290-296. PubMed ID: 27807998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of GPR142 in tryptophan-mediated enhancement of insulin secretion in obese and lean mice.
    Ueda Y; Iwakura H; Bando M; Doi A; Ariyasu H; Inaba H; Morita S; Akamizu T
    PLoS One; 2018; 13(6):e0198762. PubMed ID: 29889885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism.
    Lin HV; Efanov AM; Fang X; Beavers LS; Wang X; Wang J; Gonzalez Valcarcel IC; Ma T
    PLoS One; 2016; 11(6):e0157298. PubMed ID: 27322810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent.
    Al-Amily IM; Dunér P; Groop L; Salehi A
    Pflugers Arch; 2019 Apr; 471(4):633-645. PubMed ID: 30767071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into unbound-bound states of GPR142 receptor in a membrane-aqueous system using molecular dynamics simulations.
    Kaushik AC; Sahi S
    J Biomol Struct Dyn; 2018 May; 36(7):1788-1805. PubMed ID: 28571491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.
    Villa SR; Mishra RK; Zapater JL; Priyadarshini M; Gilchrist A; Mancebo H; Schiltz GE; Layden BT
    J Investig Med; 2017 Dec; 65(8):1116-1124. PubMed ID: 28784695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling.
    Wang J; Carrillo JJ; Lin HV
    PLoS One; 2016; 11(4):e0154452. PubMed ID: 27104960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
    Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
    Wilson JE; Kurukulasuriya R; Sinz C; Lombardo M; Bender K; Parker D; Sherer EC; Costa M; Dingley K; Li X; Mitelman S; Tong S; Bugianesi R; Ehrhardt A; Priest B; Ratliff K; Ujjainwalla F; Nargund R; Hagmann WK; Edmondson S
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2947-2951. PubMed ID: 27240550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
    Toda N; Hao X; Ogawa Y; Oda K; Yu M; Fu Z; Chen Y; Kim Y; Lizarzaburu M; Lively S; Lawlis S; Murakoshi M; Nara F; Watanabe N; Reagan JD; Tian H; Fu A; Motani A; Liu Q; Lin YJ; Zhuang R; Xiong Y; Fan P; Medina J; Li L; Izumi M; Okuyama R; Shibuya S
    ACS Med Chem Lett; 2013 Aug; 4(8):790-4. PubMed ID: 24900747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
    Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes.
    Kaushik AC; Kumar S; Wei DQ; Sahi S
    Front Chem; 2018; 6():23. PubMed ID: 29492402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice.
    Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y
    Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.
    Liu LZ; Ma T; Zhou J; Long Hu Z; Jun Zhang X; Zhen Zhang H; Zeng M; Liu J; Li L; Jiang Y; Zou Z; Wang F; Zhang L; Xu J; Wang J; Xiao F; Fang X; Zou H; Efanov AM; Thomas MK; Lin HV; Chen J
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126857. PubMed ID: 31982234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
    Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
    Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Approaches to GPCR Ligand Screening for Drug Discovery.
    Kumari P; Ghosh E; Shukla AK
    Trends Mol Med; 2015 Nov; 21(11):687-701. PubMed ID: 26481827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice.
    Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
    Biol Chem; 2014 Apr; 395(4):453-64. PubMed ID: 24323890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.
    Shuttleworth S; Townsend P; Silva F; Cecil A; Hill T; Tomassi C; Rogers H; Harrison R
    Prog Med Chem; 2011; 50():109-33. PubMed ID: 21315929
    [No Abstract]   [Full Text] [Related]  

  • 20. Lactisole inhibits the glucose-sensing receptor T1R3 expressed in mouse pancreatic β-cells.
    Hamano K; Nakagawa Y; Ohtsu Y; Li L; Medina J; Tanaka Y; Masuda K; Komatsu M; Kojima I
    J Endocrinol; 2015 Jul; 226(1):57-66. PubMed ID: 25994004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.